{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:44:41Z","timestamp":1790203481557,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2003,9,18]],"date-time":"2003-09-18T00:00:00Z","timestamp":1063843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,9,18]],"date-time":"2003-09-18T00:00:00Z","timestamp":1063843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2003,12,1]]},"DOI":"10.1038\/sj.leu.2403139","type":"journal-article","created":{"date-parts":[[2003,10,2]],"date-time":"2003-10-02T13:18:13Z","timestamp":1065100693000},"page":"2435-2443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Flavopiridol downregulates the expression of both the inducible NO synthase and p27kip1 in malignant cells from B-cell chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"17","author":[{"given":"C","family":"Billard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Ajchenbaum-Cymbalista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-P","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,9,18]]},"reference":[{"key":"BF2403139_CR1","first-page":"11","volume":"25","author":"JC Reed","year":"1998","unstructured":"Reed JC . Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 11\u201318.","journal-title":"Semin Oncol"},{"key":"BF2403139_CR2","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","volume":"82","author":"M Hanada","year":"1993","unstructured":"Hanada M, Delia D, Aiello A, Stadtmauer E, Reed J . Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820\u20131828.","journal-title":"Blood"},{"key":"BF2403139_CR3","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","volume":"91","author":"S Kitada","year":"1998","unstructured":"Kitada S, Anderson J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379\u20133389.","journal-title":"Blood"},{"key":"BF2403139_CR4","doi-asserted-by":"publisher","first-page":"37930","DOI":"10.1074\/jbc.M006558200","volume":"275","author":"S Kitada","year":"2000","unstructured":"Kitada S, Zapata JM, Andreeff M, Reed JC . Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. J Biol Chem 2000; 275: 37930\u201337936.","journal-title":"J Biol Chem"},{"key":"BF2403139_CR5","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","volume":"13","author":"CJ Sherr","year":"1999","unstructured":"Sherr CJ, Roberts JM . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501\u20131512.","journal-title":"Genes Dev"},{"key":"BF2403139_CR6","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1182\/blood.V91.12.4694","volume":"91","author":"R Vrhorac","year":"1998","unstructured":"Vrhorac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F . Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic lymphocytic leukemia. Blood 1998; 91: 4694\u20134700.","journal-title":"Blood"},{"key":"BF2403139_CR7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood.V92.3.1031","volume":"92","author":"H Zhao","year":"1998","unstructured":"Zhao H, Dugas N, Mathiot C, Dugas B, Sigaux F, Kolb JP . B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 1998; 92: 1031\u20131043.","journal-title":"Blood"},{"key":"BF2403139_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/sj.leu.2402783","volume":"17","author":"MC Levesque","year":"2003","unstructured":"Levesque MC, Misukonis MA, O'Loughlin CW, Chen Y, Beasley BE, Wilson DL et al. IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells. Leukemia 2003; 17: 442\u2013450.","journal-title":"Leukemia"},{"key":"BF2403139_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1040-8428(00)00124-4","volume":"38","author":"HH Sedlacek","year":"2001","unstructured":"Sedlacek HH . Mechanism of action of flavopiridol. Crit Rev Oncol Hematol 2001; 38: 139\u2013170.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BF2403139_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.leu.2401994","volume":"15","author":"AM Senderowicz","year":"2001","unstructured":"Senderowicz AM . Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001; 15: 1\u20139.","journal-title":"Leukemia"},{"key":"BF2403139_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1345\/aph.1A162","volume":"36","author":"S Zhai","year":"2002","unstructured":"Zhai S, Senderowicz AM, Sausville EA, Figg WD . Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 2002; 36: 905\u2013911.","journal-title":"Ann Pharmacother"},{"key":"BF2403139_CR12","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood.V90.11.4307","volume":"90","author":"A Konig","year":"1997","unstructured":"Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL . The novel cyclin-dependent kinase inhibitor flavopiridol downregulates bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90: 4307\u20134312.","journal-title":"Blood"},{"key":"BF2403139_CR13","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804.422k36_3804_3816","volume":"92","author":"JC Byrd","year":"1998","unstructured":"Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92: 3804\u20133816.","journal-title":"Blood"},{"key":"BF2403139_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1046\/j.1365-2141.2001.02895.x","volume":"114","author":"C Pepper","year":"2001","unstructured":"Pepper C, Thomas A, Hoy T, Fegan C, Bentley P . Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukemia. Br J Haematol 2001; 114: 70\u201377.","journal-title":"Br J Haematol"},{"key":"BF2403139_CR15","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/sj.leu.2401896","volume":"4","author":"JP Kolb","year":"2000","unstructured":"Kolb JP . Mechanisms involved in the pro- and anti-apoptotic effects of NO in human leukemia. Leukemia 2000; 4: 1685\u20131694.","journal-title":"Leukemia"},{"key":"BF2403139_CR16","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1038\/sj.onc.1203657","volume":"19","author":"V Frost","year":"2000","unstructured":"Frost V, Sinclair AJ . P27KIP1 is down-regulated by two different mechanisms in human lymphoid cells undergoing apoptosis. Oncogene 2000; 19: 3115\u20133120.","journal-title":"Oncogene"},{"key":"BF2403139_CR17","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990\u20134997.","journal-title":"Blood"},{"key":"BF2403139_CR18","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V84.5.1415.bloodjournal8451415","volume":"84","author":"G Koopman","year":"1994","unstructured":"Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH . Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415\u20131420.","journal-title":"Blood"},{"key":"BF2403139_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1046\/j.1365-2141.2002.03520.x","volume":"117","author":"V Roman","year":"2002","unstructured":"Roman V, Billard C, Kern C, Ferry-Dumazet H, Izard JC, Mohammad R et al. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukemia. Br J Haematol 2002; 117: 842\u2013851.","journal-title":"Br J Haematol"},{"key":"BF2403139_CR20","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1080\/1042819021000015952","volume":"43","author":"C Billard","year":"2002","unstructured":"Billard C, Izard JC, Roman V, Kern C, Mathiot C, Mentz F et al. Comparative antiproliferative and apoptotic effects of resveratrol, \u025b-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal lymphocytes. Leuk Lymphoma 2002; 43: 1991\u20132002.","journal-title":"Leuk Lymphoma"},{"key":"BF2403139_CR21","first-page":"230","volume":"63","author":"NR Wall","year":"2003","unstructured":"Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC . Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63: 230\u2013235.","journal-title":"Cancer Res"},{"key":"BF2403139_CR22","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/hep.510290419","volume":"29","author":"BS Taylor","year":"1999","unstructured":"Taylor BS, Liu S, Ganster RW, Geller DA . The role of protein phosphatases in the expression of inducible nitric oxide synthase in the rat hepatocyte. Hepatology 1999; 29: 1199\u20131207.","journal-title":"Hepatology"},{"key":"BF2403139_CR23","doi-asserted-by":"publisher","first-page":"9915","DOI":"10.1074\/jbc.274.15.9915","volume":"274","author":"M Colasanti","year":"1999","unstructured":"Colasanti M, Persichini T, Cavalieri E, Fabrizi C, Menegazzi M, Lauro GM et al. Rapid inactivation of NOS-I by lipopolysaccharide plus interferon-gamma-induced tyrosine phosphorylation. J Biol Chem 1999; 274: 9915\u20139917.","journal-title":"J Biol Chem"},{"key":"BF2403139_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/1042819021000029984","volume":"44","author":"C Pepper","year":"2003","unstructured":"Pepper C, Thomas A, Fegan C, Hoy T, Bentley P . Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leuk Lymphoma 2003; 44: 337\u2013342.","journal-title":"Leuk Lymphoma"},{"key":"BF2403139_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1084\/jem.185.4.601","volume":"185","author":"S Dimmeler","year":"1997","unstructured":"Dimmeler S, Haendeler J, Nehls M, Zeiher AM . Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta converting enzymes (ICE)-like and cysteine protease protein (CCP)-32-like proteases. J Exp Med 1997; 185: 601\u2013607.","journal-title":"J Exp Med"},{"key":"BF2403139_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1006\/bbrc.1997.7672","volume":"240","author":"J Li","year":"1995","unstructured":"Li J, Billiar TR, Talanian RV, Kim YM . Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 1995; 240: 419\u2013424.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF2403139_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1083\/jcb.200104008","volume":"154","author":"JB Mannick","year":"2001","unstructured":"Mannick JB, Shonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang K et al. S-nitrosylation of mitochondrial caspases. J Cell Biol 2001; 154: 111\u2013116.","journal-title":"J Cell Biol"},{"key":"BF2403139_CR28","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/sj.leu.2402291","volume":"15","author":"DJ Adams","year":"2001","unstructured":"Adams DJ, Levesque MC, Weinberg JB, Smith KL, Flowers JL, Moore J et al. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes. Leukemia 2001; 15: 1852\u20131859.","journal-title":"Leukemia"},{"key":"BF2403139_CR29","first-page":"2583","volume":"61","author":"L Cartee","year":"2001","unstructured":"Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hiesch KG et al. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res 2001; 61: 2583\u20132591.","journal-title":"Cancer Res"},{"key":"BF2403139_CR30","first-page":"2925","volume":"5","author":"GI Shapiro","year":"1999","unstructured":"Shapiro GI, Koestner DA, Matranga CB, Collins BJ . Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1999; 5: 2925\u20132938.","journal-title":"Clin Cancer Res"},{"key":"BF2403139_CR31","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood.V94.4.1401.416k30_1401_1408","volume":"94","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999; 94: 1401\u20131408.","journal-title":"Blood"},{"key":"BF2403139_CR32","first-page":"1149","volume":"2","author":"HK Wang","year":"2001","unstructured":"Wang HK . Flavopiridol. National Cancer Institute. Curr Opin Investig Drugs 2001; 2: 1149\u20131155.","journal-title":"Curr Opin Investig Drugs"},{"key":"BF2403139_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1054\/drup.2001.0224","volume":"4","author":"S Wadler","year":"2001","unstructured":"Wadler S . Perspectives for cancer therapies with cdk2 inhibitors. Drug Resist Updat 2001; 4: 347\u2013367.","journal-title":"Drug Resist Updat"},{"key":"BF2403139_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/sj.leu.2402464","volume":"16","author":"M Monga","year":"2002","unstructured":"Monga M, Sausville EA . Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia 2002; 16: 520\u2013526.","journal-title":"Leukemia"},{"key":"BF2403139_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00001813-200302000-00006","volume":"14","author":"S Zhai","year":"2003","unstructured":"Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA et al. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h infusion in patients with refractory neoplasms. Anticancer Drugs 2003; 14: 125\u2013135.","journal-title":"Anticancer Drugs"},{"issue":"Suppl 1","key":"BF2403139_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00280-003-0624-x","volume":"52","author":"AM Senderowicz","year":"2003","unstructured":"Senderowicz AM . Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 2003; 52 (Suppl 1): 61\u201373.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2403139_CR37","first-page":"307","volume":"9","author":"JE Karp","year":"2003","unstructured":"Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J et al. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for phase I clinical trial. Clin Cancer Res 2003; 9: 307\u2013315.","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2403139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403139","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:49:54Z","timestamp":1648777794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2403139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,18]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12,1]]}},"alternative-id":["BF2403139"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2403139","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,18]]},"assertion":[{"value":"6 March 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}